New treatment for heart failure: US Patent 9,051,387 by Richard Moss and Ariel Fernandez

The recently awarded US patent number 9051387 describes the first therapeutic disruption of a protein-protein association using a rationally designed man-made ligand, a challenge considered the holy grail in drug discovery. This invention by Richard Moss and Ariel Fernandez provides basically a treatment of heart failure. At the molecular level, the effect of the drug is the disruption of the association between myosin and its modulator MYBP-C using a competitive man-made ligand. The target was identified by cardiologist Richard Moss, while the drug itself was created by Ariel Fernandez.

US patent 9,051,387 by Richard Moss and Ariel Fernandez. The patent awarded June 9, 2015 offers a novel treatment for heart failure
US patent 9,051,387 by Richard Moss and Ariel Fernandez. The patent awarded June 9, 2015 offers a novel treatment for heart failure

This invention is featured at: US Patent and Trademark Office page, Espacenet page, Description by the University of Wisconsin-Madison, Ariel Fernandez Consultancy, Academia.edu, Ariel Fernandez’s professional page. This patent marks the dawn of the new paradigm for drug discovery based on epistructural biology, the new discipline introduced by Ariel Fernandez.

You may read the press release for Richard Moss and Ariel Fernandez’ patent US9051387 as featured in YahooMarketWatch, or in the original form prior to distribution in WebWire.

 

RELATED READING

CV for Ariel Fernandez (updated May 18, 2015)

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s